MEI Pharma, Inc. (NASDAQ:MEIP) Short Interest Update

MEI Pharma, Inc. (NASDAQ:MEIP) was the target of a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 5,800 shares, a growth of 38.1% from the February 13th total of 4,200 shares. Based on an average daily volume of 19,600 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.1% of the shares of the stock are short sold.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on shares of MEI Pharma in a report on Saturday. They issued a “buy” rating for the company.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Northern Trust Corp grew its holdings in MEI Pharma by 54.5% during the fourth quarter. Northern Trust Corp now owns 35,596 shares of the company’s stock worth $88,000 after acquiring an additional 12,561 shares during the period. Toronto Dominion Bank acquired a new position in MEI Pharma during the fourth quarter worth about $62,000. World Investment Advisors LLC acquired a new position in MEI Pharma during the third quarter worth about $71,000. Corsair Capital Management L.P. acquired a new position in MEI Pharma during the third quarter worth about $69,000. Finally, Virtu Financial LLC purchased a new stake in shares of MEI Pharma during the fourth quarter valued at $26,000. 52.38% of the stock is owned by institutional investors and hedge funds.

MEI Pharma Trading Up 0.2 %

MEIP stock traded up $0.01 during trading on Tuesday, hitting $2.33. The company had a trading volume of 476 shares, compared to its average volume of 45,825. The firm has a market capitalization of $15.49 million, a price-to-earnings ratio of -0.41 and a beta of 0.76. The business has a 50 day moving average of $2.66 and a 200 day moving average of $2.77. MEI Pharma has a fifty-two week low of $2.28 and a fifty-two week high of $4.15.

MEI Pharma (NASDAQ:MEIP) last released its earnings results on Wednesday, February 12th. The company reported ($0.48) earnings per share (EPS) for the quarter. As a group, equities analysts predict that MEI Pharma will post -5.1 EPS for the current year.

MEI Pharma Company Profile

MEI Pharma, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies.